These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18729281)

  • 1. [Pharmazie in unserer Zeit 5/2008].
    Dingermann T; Laufer S; Winckler T
    Pharm Unserer Zeit; 2008; 37(5):349. PubMed ID: 18729281
    [No Abstract]   [Full Text] [Related]  

  • 2. [Targeting Ras related proteins for leukemia therapy].
    Kimura S; Maekawa T
    Rinsho Ketsueki; 2005 Mar; 46(3):179-86. PubMed ID: 16447712
    [No Abstract]   [Full Text] [Related]  

  • 3. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

  • 4. A functional approach to questions about life, death, and phosphorylation.
    Bernards R
    Cancer Cell; 2005 Jun; 7(6):503-4. PubMed ID: 15950899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase inhibitors as a therapeutic modality.
    Levitzki A
    Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia.
    Mughal TI; Goldman JM
    Clin Med (Lond); 2006; 6(6):526-8. PubMed ID: 17228548
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tyrosine kinase inhibitor STI571--a breakthrough in leukemia treatment?].
    Czechowska A; Błasiak J
    Postepy Biochem; 2003; 49(3):157-67. PubMed ID: 15083608
    [No Abstract]   [Full Text] [Related]  

  • 8. Bench to bedside: BRCA: from therapeutic target to therapeutic shield.
    Shah NP
    Nat Med; 2008 May; 14(5):495-6. PubMed ID: 18463659
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
    Levitzki A
    Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans].
    Moiseenko VM; Chudenko VA; Orlova RV; Imianitov EN; Matsko DE; Gafton GI; Kochnev VA; Protsenko SA; Mikhaĭlichenko TD; Nogaeva TKh
    Vopr Onkol; 2008; 54(5):656-60. PubMed ID: 19069485
    [No Abstract]   [Full Text] [Related]  

  • 13. Gleevec casts a pox on poxviruses.
    McFadden G
    Nat Med; 2005 Jul; 11(7):711-2. PubMed ID: 16015355
    [No Abstract]   [Full Text] [Related]  

  • 14. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib.
    Drechsler M; Hildebrandt B; Kündgen A; Germing U; Royer-Pokora B
    Ann Hematol; 2007 May; 86(5):353-4. PubMed ID: 17211520
    [No Abstract]   [Full Text] [Related]  

  • 15. [Autophagy in hematologic malignancies].
    Adachi S
    Rinsho Ketsueki; 2009 Oct; 50(10):1531-8. PubMed ID: 19915363
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib: the narrow line between immune tolerance and activation.
    Mohty M; Blaise D; Olive D; Gaugler B
    Trends Mol Med; 2005 Sep; 11(9):397-402. PubMed ID: 16087402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OCT-1 as a determinant of response to antileukemic treatment.
    Engler JR; Hughes TP; White DL
    Clin Pharmacol Ther; 2011 Apr; 89(4):608-11. PubMed ID: 21346750
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacogenetics and tailored drug therapy].
    Nielsen FC; Borregaard N
    Ugeskr Laeger; 2009 Mar; 171(10):790-4. PubMed ID: 19265602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.